Imugene Ltd Asset Resilience Ratio

Latest as of December 2025: 23.07%

Imugene Ltd asset resilience ratio. Imugene Ltd (IMU) has an Asset Resilience Ratio of 23.07% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IMU defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$15.61 Million
≈ $11.04 Million USD Cash + Short-term Investments

Total Assets

AU$67.67 Million
≈ $47.88 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Imugene Ltd (1995–2025)

Asset resilience ratio of Imugene Ltd from 1995 to 2025. This chart shows how Imugene Ltd's Asset Resilience Ratio has changed over time. Read IMU total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Imugene Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IMU total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$14.14 Million 20.89%
Short-term Investments AU$1.47 Million 2.18%
Total Liquid Assets AU$15.61 Million 23.07%

Asset Resilience Insights

  • Good Liquidity Position: Imugene Ltd maintains a healthy 23.07% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Imugene Ltd Industry Peers by Asset Resilience Ratio

Compare Imugene Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Imugene Ltd Asset Resilience Ratio by Year (1995–2025)

Imugene Ltd asset resilience ratio by year from 1995 to 2025. The table below shows the annual Asset Resilience Ratio data for Imugene Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 2.49% AU$2.08 Million
≈ $1.47 Million
AU$83.59 Million
≈ $59.14 Million
-31.20pp
2024-06-30 33.69% AU$51.01 Million
≈ $36.09 Million
AU$151.40 Million
≈ $107.12 Million
+8.55pp
2023-06-30 25.14% AU$49.54 Million
≈ $35.05 Million
AU$197.06 Million
≈ $139.43 Million
+5.49pp
2022-06-30 19.65% AU$29.00 Million
≈ $20.52 Million
AU$147.61 Million
≈ $104.44 Million
-9.60pp
2021-06-30 29.25% AU$21.00 Million
≈ $14.86 Million
AU$71.81 Million
≈ $50.81 Million
-9.10pp
2020-06-30 38.34% AU$25.00 Million
≈ $17.69 Million
AU$65.20 Million
≈ $46.14 Million
-17.52pp
2019-06-30 55.87% AU$17.20 Million
≈ $12.17 Million
AU$30.78 Million
≈ $21.78 Million
+9.62pp
2018-06-30 46.25% AU$7.82 Million
≈ $5.53 Million
AU$16.91 Million
≈ $11.97 Million
+8.27pp
2017-06-30 37.97% AU$4.81 Million
≈ $3.41 Million
AU$12.68 Million
≈ $8.97 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$9.54 Million
≈ $6.75 Million
--
1996-06-30 4.18% AU$387.00K
≈ $273.83K
AU$9.25 Million
≈ $6.54 Million
+0.33pp
1995-06-30 3.86% AU$460.00K
≈ $325.48K
AU$11.93 Million
≈ $8.44 Million
--
pp = percentage points

About Imugene Ltd

AU:IMU Australia Biotechnology
Market Cap
$11.63 Million
AU$16.44 Million AUD
Market Cap Rank
#26529 Global
#1198 in Australia
Share Price
AU$0.03
Change (1 day)
-2.94%
52-Week Range
AU$0.03 - AU$0.39
All Time High
AU$0.61
About

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more